Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Merck Sharp & Dohme LLC
Vejle Hospital
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Ipsen
AstraZeneca
Sun Yat-sen University
Arcus Biosciences, Inc.
Alliance for Clinical Trials in Oncology
Akeso
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Summit Therapeutics
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Jazz Pharmaceuticals
Shanghai Henlius Biotech
Akeso
AstraZeneca
Second Affiliated Hospital, School of Medicine, Zhejiang University
Astellas Pharma Inc
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Alliance for Clinical Trials in Oncology
Astellas Pharma Inc
University of Campania Luigi Vanvitelli
National Cancer Institute (NCI)
Universitätsmedizin Mannheim
NRG Oncology
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University
Ruijin Hospital
J-Pharma Co., Ltd.
RemeGen Co., Ltd.
NRG Oncology
UNICANCER
Canadian Cancer Trials Group
TransThera Sciences (Nanjing), Inc.
Children's Oncology Group
Hospices Civils de Lyon
Suzhou Transcenta Therapeutics Co., Ltd.
Merck Sharp & Dohme LLC
Charite University, Berlin, Germany
Revolution Medicines, Inc.
Sun Yat-sen University
Shanghai Cancer Hospital, China
Gruppo Oncologico del Nord-Ovest
Maimónides Biomedical Research Institute of Córdoba